Zobrazeno 1 - 10
of 76
pro vyhledávání: '"I H, Krakoff"'
Publikováno v:
Journal of Clinical Oncology. 9:707-709
Autor:
D M, Moore, D V, Kalvakolanu, S M, Lippman, J J, Kavanagh, W K, Hong, E C, Borden, M, Paredes-Espinoza, I H, Krakoff
Publikováno v:
Seminars in hematology. 31(4 Suppl 5)
Various combinations of retinoids, metabolic and synthetic derivatives of vitamin A, and interferons (IFNs) have demonstrated synergistic antiproliferative, differentiating, and antiangiogenic activity in some human hematologic and solid-tumor system
Publikováno v:
Anticancer research. 13(2)
FK 973, a novel substituted dihydrobenzoxazine structurally similar to mitomycin C, is a derivative of the product isolated from Streptomyces sandaensis. In vitro and in rodents, it is a potent antitumor agent. During Phase I clinical trials, we eval
Autor:
D H, Ho, W P, Covington, R, Pazdur, N S, Brown, J, Kuritani, R A, Newman, M N, Raber, I H, Krakoff
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 20(6)
Phase I clinical trials of the combination of oral uracil with ftorafur (Ft) were conducted in patients with solid tumors over either a 5-day (345 mg/m2/day) or a 28-day (160 mg/m2/day) period. The uracil dose, which was four times the Ft dose (molar
Autor:
I H, Krakoff
Publikováno v:
Seminars in oncology. 19(2 Suppl 5)
Autor:
D H, Ho, N, Brown, J R, Lin, W, Covington, R A, Newman, M, Raber, R, Amato, S, Schmidt, I H, Krakoff
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 19(3)
The clinical pharmacology of fazarabine (1-beta-D-arabinofuranosyl-5-azacytosine), a structural analogue of 1-beta-D-arabinofuranosylcytosine (ara-C) and 5-azacytidine, was assessed in 14 patients with various malignancies during a phase I trial. Sin
Autor:
I H, Krakoff
Publikováno v:
Cancer. 67
A major responsibility for all physicians, but particularly for oncologists, is to recognize the time when active antitumor treatment ceases to have a rational basis. The decision to treat or not to treat at any stage of disease requires an analysis
Publikováno v:
Research communications in chemical pathology and pharmacology. 67(1)
LY195448(R) (a phenethanolamine derivative that has demonstrated cytotoxic activity against cell cultures in vitro but that exhibited a hypotensive side effect during phase I trials), its p-hydroxy and acid metabolites, and a noncytotoxic S-stereoiso
Publikováno v:
Cancer treatment reports. 68(12)
Publikováno v:
Cancer treatment reports. 71(12)
A phase I study of benzisoquinolinedione (amonafide) was conducted in 30 patients with advanced solid tumors refractory to conventional therapy. The starting dose was 10 mg/m2/day X 5 days and the highest tolerated dose was 625 mg/m2/day X 5. The dai